<DOC>
	<DOCNO>NCT00488475</DOCNO>
	<brief_summary>The diagnosis , evaluation treatment rheumatoid arthritis ( RA ) continue undergo rapid change . Randomized control trial TEMPO study demonstrate efficacy safety combination etanercept methotrexate . Importantly , TEMPO study show patient treat etanercept methotrexate could reach new therapeutic goal low disease activity remission , physician , patient , payer longer prepared accept goal `` Reduction symptom '' . RCT important powerful tool assess efficacy safety limitation term generalisability . In order ass health economics , clinical effectiveness safety etanercept , need measure perform observational study unselected patient . This study aim provide holistic assessment patient receive etanercept real world set . This include center would normally take part RCT . The study ass treatment etanercept descriptive statistic follow parameter : Health economic , Safety , Effectiveness . In addition , previous study similar design , 3 month duration ( 101354 ) , allow comparison historical data . Since previous study , number significant change : Introduction new formulation etanercept ( Enbrel® 50mg · weekly ) , Definition early RA modify short disease duration ( 3 month 1 year ) .</brief_summary>
	<brief_title>Observational Trial With Enbrel</brief_title>
	<detailed_description>Non-interventional study : subject select accord usual clinical practice physician</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Clinical diagnosis rheumatoid arthritis Sepsis risk sepsis , Acute infection , Hypersensitivity Etanercept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>